Review on Fluorinated Nucleoside/non-nucleoside FDA-approved Antiviral Drugs

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 Nov 9

PMID 36348998

Authors

Magda M F Ismail

Mohammed Salah Ayoup

Affiliations

Soon will be listed here.

Abstract

FDA-approved antiviral agents represent an important class that has attracted attention in recent years to combat current and future threats of viral pandemics. Fluorine ameliorates the electronic, lipophilic and steric problems of drugs. Additionally, fluorine can prolong drug activity and improve metabolic stability, thereby, modifying their pharmacodynamic and pharmacokinetic character. Herein, we summarized the fluorinated FDA-approved antiviral agents, dealing with biological aspects, mechanisms of action, and synthetic pathways.

Citing Articles

Synthesis of Fluorinated Nucleosides/Nucleotides and Their Antiviral Properties.

Kothapalli Y, Jones R, Chu C, Singh U Molecules. 2024; 29(10).

PMID: 38792251 PMC: 11124531. DOI: 10.3390/molecules29102390.

Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as novel HIV-1 integrase strand transfer inhibitors.

Zhang R, Chen G, Wang W, Wang Y, Zhang W, Chen T RSC Adv. 2024; 14(13):9020-9031.

PMID: 38500630 PMC: 10945512. DOI: 10.1039/d3ra08320a.

Recent Advances in Molecular Mechanisms of Nucleoside Antivirals.

Kamzeeva P, Aralov A, Alferova V, Korshun V Curr Issues Mol Biol. 2023; 45(8):6851-6879.

PMID: 37623252 PMC: 10453654. DOI: 10.3390/cimb45080433.

References

Furman P, Fyfe J, St Clair M, Weinhold K, Rideout J, Freeman G . Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986; 83(21):8333-7. PMC: 386922. DOI: 10.1073/pnas.83.21.8333. View

Grosenbach D, Jordan R, Hruby D . Development of the small-molecule antiviral ST-246 as a smallpox therapeutic. Future Virol. 2011; 6(5):653-671. PMC: 3151656. DOI: 10.2217/fvl.11.27. View

Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen P . Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol. 1995; 2(5):407-15. DOI: 10.1038/nsb0595-407. View

Bohm H, Banner D, Bendels S, Kansy M, Kuhn B, Muller K . Fluorine in medicinal chemistry. Chembiochem. 2004; 5(5):637-43. DOI: 10.1002/cbic.200301023. View

Serna-Arbelaez M, Florez-Sampedro L, Orozco L, Ramirez K, Galeano E, Zapata W . Natural Products with Inhibitory Activity against Human Immunodeficiency Virus Type 1. Adv Virol. 2021; 2021:5552088. PMC: 8181102. DOI: 10.1155/2021/5552088. View

Ray A, Schinazi R, Murakami E, Basavapathruni A, Shi J, Zorca S . Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase. Antivir Chem Chemother. 2003; 14(3):115-25. DOI: 10.1177/095632020301400301. View

Turner S, Strohbach J, Tommasi R, Aristoff P, Johnson P, Skulnick H . Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem. 1998; 41(18):3467-76. DOI: 10.1021/jm9802158. View

Vergani B, Rusconi S . Tipranavir in the protease inhibitors arena. Drugs R D. 2011; 11(4):291-3. PMC: 3585897. DOI: 10.2165/11594570-000000000-00000. View

DCruz O, Uckun F . Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother. 2006; 57(3):411-23. DOI: 10.1093/jac/dki464. View

10.

Tchesnokov E, Gilbert C, Boivin G, Gotte M . Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet. J Virol. 2006; 80(3):1440-50. PMC: 1346920. DOI: 10.1128/JVI.80.3.1440-1450.2006. View

11.

Santi D, Sakai T . Thymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-2'-deoxyuridylic acid. Biochemistry. 1971; 10(19):3598-607. DOI: 10.1021/bi00795a018. View

12.

Kuritzkes D . HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS. 2009; 4(2):82-7. PMC: 2753507. DOI: 10.1097/COH.0b013e328322402e. View

13.

Diana G, Rudewicz P, Pevear D, Nitz T, Aldous S, Aldous D . Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. J Med Chem. 1995; 38(8):1355-71. DOI: 10.1021/jm00008a014. View

14.

Filler R, Saha R . Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights. Future Med Chem. 2011; 1(5):777-91. DOI: 10.4155/fmc.09.65. View

15.

Serrao E, Odde S, Ramkumar K, Neamati N . Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology. 2009; 6:25. PMC: 2660292. DOI: 10.1186/1742-4690-6-25. View

16.

Frampton J, Perry C . Emtricitabine: a review of its use in the management of HIV infection. Drugs. 2005; 65(10):1427-48. DOI: 10.2165/00003495-200565100-00008. View

17.

Kitchen C, Kitchen S, Dubin J, Gottlieb M . Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. Clin Infect Dis. 2001; 33(4):466-72. DOI: 10.1086/321900. View

18.

HEIDELBERGER C, Parsons D, REMY D . SYNTHESES OF 5-TRIFLUOROMETHYLURACIL AND 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE. J Med Chem. 1964; 7:1-5. DOI: 10.1021/jm00331a001. View

19.

De Clercq E, Li G . Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016; 29(3):695-747. PMC: 4978613. DOI: 10.1128/CMR.00102-15. View

20.

Manabe T, Kambayashi D, Akatsu H, Kudo K . Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021; 21(1):489. PMC: 8159019. DOI: 10.1186/s12879-021-06164-x. View